目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 27)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIES COVERED
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 31)
2.1 RESEARCH DATA
FIGURE 1 HLA TYPING MARKET: RESEARCH METHODOLOGY
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.1.2.3 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 LIMITATIONS AND ASSOCIATED RISKS
2.8 MARKET: RECESSION IMPACT

3 EXECUTIVE SUMMARY (Page No. - 43)
FIGURE 7 HLA TYPING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 8 MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 11 ASIA PACIFIC REGION TO DOMINATE MARKET DURING FORECAST PERIOD

4 PREMIUM INSIGHTS (Page No. - 47)
4.1 HLA TYPING MARKET OVERVIEW
FIGURE 12 INCREASING NUMBER OF ORGAN TRANSPLANTATIONS AND RISING ADOPTION OF DONOR RECIPIENT CROSS-MATCHING TO DRIVE MARKET
4.2 MARKET, BY DIAGNOSTIC APPLICATIONS, 2023 VS. 2028 (USD MILLION)
FIGURE 13 DONOR RECIPIENT CROSS-MATCHING SEGMENT TO DOMINATE DIAGNOSTIC APPLICATIONS DURING FORECAST PERIOD
4.3 MARKET: ASIA PACIFIC, BY PRODUCT & SERVICE (2022)
FIGURE 14 REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA
4.4 MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 15 CHINA TO DOMINATE MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 51)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 HLA TYPING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising number of organ transplantation procedures
5.2.1.2 Rising technological advancements in HLA typing
5.2.1.3 Increasing funding investments for research activities
TABLE 2 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR HLA TYPING PRODUCTS, 2019-2022
5.2.1.4 Growing prevalence of infectious diseases
5.2.2 RESTRAINTS
5.2.2.1 High cost of HLA typing products
TABLE 3 COST OF ASSAYS FOR KEY NGS AND PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2020)
5.2.2.2 Limited reimbursements for target procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Rising adoption of cross-matching and chimerism testing procedures
5.2.3.2 Growing awareness of organ donations
5.2.4 CHALLENGES
5.2.4.1 Limited number of organ donations and long waiting lists for transplantations
5.2.4.2 Shortage of skilled professionals
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 REGULATORY ANALYSIS
5.4.1 NORTH AMERICA
5.4.1.1 US
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.4.1.2 Canada
TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.4.2 EUROPE
5.4.3 ASIA PACIFIC
5.4.3.1 Japan
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
5.4.3.2 China
TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.4.3.3 India
5.5 MARKET: ECOSYSTEM MAPPING
FIGURE 17 ECOSYSTEM COVERAGE
5.6 VALUE CHAIN ANALYSIS
5.6.1 RESEARCH AND DEVELOPMENT
5.6.2 MANUFACTURING AND ASSEMBLY
5.6.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
FIGURE 18 VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.7.1 PROMINENT COMPANIES
5.7.2 SMALL AND MEDIUM-SIZED ENTERPRISES
FIGURE 19 SUPPLY CHAIN ANALYSIS
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HLA TYPING PRODUCTS
5.8.2 BUYING CRITERIA
FIGURE 21 KEY BUYING CRITERIA FOR HLA TYPING PRODUCTS
TABLE 11 KEY BUYING CRITERIA FOR HLA TYPING PRODUCTS
5.9 PATENT ANALYSIS
FIGURE 22 TOP 10 PATENT APPLICANTS FOR HLA TYPING
5.10 IMPACT OF RECESSION ON MARKET

6 HLA TYPING MARKET, BY PRODUCT & SERVICE (Page No. - 69)
6.1 INTRODUCTION
TABLE 12 MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
6.2 REAGENTS & CONSUMABLES
6.2.1 WIDE APPLICATIONS OF MOLECULAR ASSAY TECHNIQUES TO DRIVE MARKET
TABLE 13 MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 GROWING ADOPTION OF PCR AND NGS INSTRUMENTS AMONG CROS AND HOSPITALS TO FUEL MARKET
TABLE 14 MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 RISING DEMAND FOR AUTOMATION AND DIGITALIZATION IN LAB PROCEDURES TO DRIVE MARKET
TABLE 15 MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)

7 HLA TYPING MARKET, BY TECHNOLOGY (Page No. - 73)
7.1 INTRODUCTION
TABLE 16 MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
7.2 MOLECULAR ASSAY TECHNOLOGIES
TABLE 17 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 18 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 19 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 20 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2021-2028 (USD MILLION)
TABLE 21 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)
7.2.1 PCR-BASED MOLECULAR ASSAYS
TABLE 22 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 23 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2021-2028(USD MILLION)
TABLE 24 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 25 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 2021-2028 (USD MILLION)
TABLE 26 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2021-2028 (USD MILLION)
7.2.1.1 Sequence-specific Primer-PCR
7.2.1.1.1 Expanding distribution channels of key PCR manufacturers to support market growth
TABLE 27 MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2021-2028 (USD MILLION)
7.2.1.2 Sequence-specific Oligonucleotide-PCR
7.2.1.2.1 Rising need for SSO-PCR-based molecular assays in disease diagnosis to drive market
TABLE 28 MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2021-2028 (USD MILLION)
7.2.1.3 Real-time PCR
7.2.1.3.1 Increasing preference for genome-based molecular diagnostics to support market growth
TABLE 29 MARKET FOR REAL-TIME PCR, BY REGION, 2021-2028 (USD MILLION)
7.2.1.4 Other PCR-based molecular assays
TABLE 30 MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2021-2028 (USD MILLION)
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
TABLE 31 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 32 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 33 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 34 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 2021-2028 (USD MILLION)
TABLE 35 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2021-2028 (USD MILLION)
7.2.2.1 Sanger sequencing
7.2.2.1.1 Rising end-user preference for low-cost and efficient DNA sequencing technology to drive segment growth
TABLE 36 MARKET FOR SANGER SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
7.2.2.2 Next-generation Sequencing
7.2.2.2.1 High scalability, low turnaround time, and high throughput capabilities to drive segment growth
TABLE 37 MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
7.2.2.3 Other sequencing-based molecular assays
TABLE 38 MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2021-2028 (USD MILLION)
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
7.3.1 HIGH PREFERENCE OF MOLECULAR-BASED TECHNIQUES TO RESTRAIN MARKET
TABLE 39 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 40 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 41 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2021-2028 (USD MILLION)
TABLE 42 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

8 HLA TYPING MARKET, BY APPLICATION (Page No. - 89)
8.1 INTRODUCTION
TABLE 43 MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
8.2 DIAGNOSTIC APPLICATIONS
TABLE 44 MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 45 MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
8.2.1 DONOR-RECIPIENT CROSS-MATCHING
8.2.1.1 Rising need for histocompatibility cross-matching in organ transplantation to drive market
TABLE 46 MARKET FOR DONOR-RECIPIENT CROSS-MATCHING, BY REGION, 2021-2028 (USD MILLION)
8.2.2 INFECTIOUS DISEASE TESTING
8.2.2.1 Rising burden of infectious diseases to drive adoption of HLA antigen screening
TABLE 47 MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2021-2028 (USD MILLION)
8.2.3 CANCER DIAGNOSIS & PREVENTION
8.2.3.1 Wide availability of advanced NGS techniques to drive adoption of HLA typing in cancer diagnostics
TABLE 48 MARKET FOR CANCER DIAGNOSIS & PREVENTION, BY REGION, 2021-2028 (USD MILLION)
8.2.4 TRANSFUSION THERAPY
8.2.4.1 Minimal risk of fatal disorders during blood transfusions to drive adoption of HLA typing
TABLE 49 MARKET FOR TRANSFUSION THERAPY, BY REGION, 2021-2028(USD MILLION)
8.2.5 OTHER DIAGNOSTIC APPLICATIONS
TABLE 50 MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
8.3 RESEARCH APPLICATIONS
8.3.1 RISING FUNDING FOR RESEARCH AND EXPANDING APPLICATIONS OF HLA TYPING TO DRIVE MARKET
TABLE 51 MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

9 HLA TYPING MARKET, BY END USER (Page No. - 97)
9.1 INTRODUCTION
TABLE 52 MARKET, BY END USER, 2021-2028 (USD MILLION)
9.2 COMMERCIAL SERVICE PROVIDERS
9.2.1 RISING ESTABLISHMENT OF REFERENCE LABORATORIES IN EMERGING ECONOMIES TO DRIVE MARKET
TABLE 53 MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION, 2021-2028 (USD MILLION)
9.3 HOSPITALS AND TRANSPLANT CENTERS
9.3.1 INCREASING DEMAND FOR ADVANCED EQUIPMENT IN HOSPITALS TO DRIVE MARKET
TABLE 54 MARKET FOR HOSPITALS AND TRANSPLANT CENTERS, BY REGION, 2021-2028 (USD MILLION)
9.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
9.4.1 RISING GOVERNMENT SUPPORT FOR CANCER RESEARCH TO BOOST MARKET GROWTH
TABLE 55 MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2021-2028(USD MILLION)

10 HLA TYPING MARKET, BY REGION (Page No. - 101)
10.1 INTRODUCTION
TABLE 56 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 23 MARKET: NORTH AMERICA SNAPSHOT
TABLE 57 NORTH AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 58 NORTH AMERICA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 59 NORTH AMERICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 60 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 61 NORTH AMERICA: MARKET, BY APPLICATION 2021-2028 (USD MILLION)
TABLE 62 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.2.1 US
10.2.1.1 High volume of stem cell and bone marrow transplantation procedures to drive market
TABLE 63 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN US, 2021-2022
TABLE 64 NEW CANCER CASES IN US, 2021
TABLE 65 US: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 66 US: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 67 US: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.2.2 CANADA
10.2.2.1 High prevalence of cancer to drive adoption of HLA typing
TABLE 68 CANADA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 69 CANADA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 70 CANADA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.3 EUROPE
TABLE 71 EUROPE: HLA TYPING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 72 EUROPE: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 73 EUROPE: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 74 EUROPE: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 75 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 76 EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 77 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Strong presence of established manufacturers for HLA typing products to drive market
TABLE 78 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN GERMANY, BY TYPE, 2020-2021
TABLE 79 TARGET DISEASE INCIDENCE IN GERMANY (2021)
TABLE 80 NEW CANCER CASES IN GERMANY, BY ORGAN (2021)
TABLE 81 GERMANY: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 82 GERMANY: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 83 GERMANY: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.3.2 UK
10.3.2.1 Rising prevalence of autoimmune diseases to drive market
TABLE 84 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN UK, 2021-2022
TABLE 85 TARGET DaISEASE INCIDENCE IN UK, 2021
TABLE 86 NEW CANCER CASES IN UK, 2021
TABLE 87 UK: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 88 UK: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 89 UK: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rising organ rejection rate to drive market
TABLE 90 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN FRANCE, 2021-2022
TABLE 91 NEW CANCER CASES IN FRANCE, 2021
TABLE 92 FRANCE: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 93 FRANCE: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, 2021-2028 (USD MILLION)
TABLE 94 FRANCE: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Increasing acceptance of molecular assay technologies for personalized medicine to drive market
TABLE 95 ITALY: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 96 ITALY: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 97 ITALY: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Rising number of solid-organ transplantation procedures to support market growth
TABLE 98 SPAIN: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 99 SPAIN: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 100 SPAIN: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 101 REST OF EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 102 REST OF EUROPE: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 103 REST OF EUROPE: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 24 HLA TYPING MARKET: ASIA PACIFIC SNAPSHOT
TABLE 104 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 105 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 106 ASIA PACIFIC: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 107 ASIA PACIFIC: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 108 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 109 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 110 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Rising adoption of HLA typing for donor-recipient screening to drive market
TABLE 111 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN CHINA, 2021-2022
TABLE 112 NEW CANCER CASES IN CHINA, 2021
TABLE 113 CHINA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 114 CHINA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 115 CHINA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.4.2 INDIA
10.4.2.1 Government initiatives to provide free availability of HLA typing products to drive market
TABLE 116 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN INDIA, 2021-2022
TABLE 117 NEW CANCER CASES IN INDIA, 2021
TABLE 118 INDIA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 119 INDIA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 120 INDIA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Increasing budgetary allocations for healthcare to support market growth
TABLE 121 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN JAPAN, 2021-2022
TABLE 122 NEW CANCER CASES IN JAPAN, 2021
TABLE 123 JAPAN: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 124 JAPAN: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 125 JAPAN: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 Rising prevalence of coeliac disease to drive adoption of HLA typing
TABLE 126 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN AUSTRALIA, 2021-2022
TABLE 127 NEW CANCER CASES IN AUSTRALIA, 2021
TABLE 128 AUSTRALIA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 129 AUSTRALIA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 130 AUSTRALIA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Rising adoption of next-generation exome sequencing to drive market
TABLE 131 SOUTH KOREA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 132 SOUTH KOREA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 133 SOUTH KOREA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 134 REST OF ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 135 REST OF ASIA PACIFIC: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 136 REST OF ASIA PACIFIC: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
10.5 LATIN AMERICA
TABLE 137 LATIN AMERICA: HLA TYPING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 138 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 139 LATIN AMERICA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 140 LATIN AMERICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 141 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 142 LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 143 LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Supportive government regulations for adoption of advanced technologies to drive market
TABLE 144 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN BRAZIL, 2021-2022
TABLE 145 NEW CANCER CASES IN BRAZIL, 2021
TABLE 146 BRAZIL: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 147 BRAZIL: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 148 BRAZIL: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Improving accessibility and affordability of healthcare services to support market growth
TABLE 149 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN MEXICO, 2021-2022
TABLE 150 NEW CANCER CASES IN MEXICO, 2021
TABLE 151 MEXICO: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 152 MEXICO: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 153 MEXICO: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 154 REST OF LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 155 REST OF LATIN AMERICA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 156 REST OF LATIN AMERICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
10.6 MIDDLE EAST AND AFRICA
10.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO FUEL MARKET
TABLE 157 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 158 MIDDLE EAST & AFRICA: MARKET FOR PCR-BASED MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 159 MIDDLE EAST & AFRICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAY TECHNOLOGIES ASSAYS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 160 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 161 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 162 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 146)
11.1 INTRODUCTION
11.2 STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 163 HLA TYPING MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
11.3 MARKET SHARE ANALYSIS
FIGURE 25 MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
11.4 COMPETITIVE LEADERSHIP MAPPING
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 26 MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
11.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2021)
11.5.1 PROGRESSIVE COMPANIES
11.5.2 RESPONSIVE COMPANIES
11.5.3 DYNAMIC COMPANIES
11.5.4 STARTING BLOCKS
FIGURE 27 MARKET: COMPANY EVALUATION MATRIX FOR SMES/STARTUPS, 2021
11.6 COMPETITIVE BENCHMARKING
TABLE 164 MARKET: PRODUCT ANALYSIS FOR KEY PLAYERS
TABLE 165 MARKET: APPLICATION FOOTPRINT ANALYSIS FOR KEY PLAYERS
TABLE 166 MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
11.7 COMPETITIVE SCENARIO
11.7.1 PRODUCT LAUNCHES
TABLE 167 MARKET: PRODUCT LAUNCHES (2019-2022)
11.7.2 DEALS
TABLE 168 MARKET: DEALS (2019-2022)

12 COMPANY PROFILES (Page No. - 158)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 BD
TABLE 169 BD: COMPANY OVERVIEW (2021)
FIGURE 28 BD: COMPANY SNAPSHOT (2021)
12.1.2 BIO-RAD LABORATORIES, INC.
TABLE 170 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW (2021)
FIGURE 29 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
12.1.3 F. HOFFMAN-LA ROCHE LTD.
TABLE 171 F. HOFFMAN-LA ROCHE LTD: COMPANY OVERVIEW (2021)
FIGURE 30 F. HOFFMAN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
12.1.4 CAREDX, INC.
TABLE 172 CAREDX, INC.: COMPANY OVERVIEW (2021)
FIGURE 31 CAREDX, INC.: COMPANY SNAPSHOT (2021)
12.1.5 HOLOGIC, INC.
TABLE 173 HOLOGIC, INC.: COMPANY OVERVIEW (2021)
FIGURE 32 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
12.1.6 ILLUMINA, INC.
TABLE 174 ILLUMINA, INC.: COMPANY OVERVIEW (2021)
FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
12.1.7 IMMUCOR, INC.
TABLE 175 IMMUCOR, INC.: COMPANY OVERVIEW (2021)
FIGURE 34 IMMUCOR, INC.: COMPANY SNAPSHOT (2021)
12.1.8 OMIXON INC.
TABLE 176 OMIXON INC.: COMPANY OVERVIEW (2021)
12.1.9 QIAGEN N.V.
TABLE 177 QIAGEN N.V.: COMPANY OVERVIEW (2021)
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
12.1.10 TAKARA BIO INC.
TABLE 178 TAKARA BIO INC.: COMPANY OVERVIEW (2021)
FIGURE 36 TAKARA BIO, INC: COMPANY SNAPSHOT (2021)
12.1.11 THERMO FISHER SCIENTIFIC
TABLE 179 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW (2021)
FIGURE 37 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
12.1.12 BIOFORTUNA LIMITED
12.1.13 GENDX
TABLE 180 GENDX: COMPANY OVERVIEW (2021)
12.2 OTHER PLAYERS
12.2.1 FUJIREBIO
12.2.2 CREATIVE BIOLABS
12.2.3 ALPHA BIOTECH LIMITED
12.2.4 BAG DIAGNOSTICS GMBH
12.2.5 HANSA BIOPHARMA AB
12.2.6 HISTOGENETICS LLC
12.2.7 PACBIO
12.2.8 TBG DIAGNOSTICS LIMITED
12.2.9 INNO-TRAIN DIAGNOSTIK GMBH
12.2.10 KRISHGEN BIOSYSTEMS
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 214)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS